We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
ATAI Life Sciences NV | NASDAQ:ATAI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.91 | 1.95 | 2.00 | 300 | 12:00:12 |
By Denny Jacob
International stocks trading in New York closed mostly higher on Tuesday.
The S&P/BNY Mellon index of American depositary receipts edged up 1.4% to 123.62. The European index gained 1.5% to 121.37. The Asian index ticked up 1.5% to 135.64. The Latin American index ticked down 0.4% to 186.28, while the emerging-markets index moved up 0.8% to 233.10.
AstraZeneca PLC was among those whose ADRs traded actively.
The pharmaceutical giant moved up 1.3% after the company said that a Phase 3 trial of its Fasenra treatment for eosinophilic esophagitis passed one dual-primary endpoint but failed the other.
Clinical-stage biopharmaceutical company atai Life Sciences gained 4.5% after it said it completed the enrollment of its Phase 2a clinical trial of PCN-101, a stereoisomer of ketamine being developed for treatment-resistant depression, with topline results expected around 2022 year-end.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
October 25, 2022 18:27 ET (22:27 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year ATAI Life Sciences NV Chart |
1 Month ATAI Life Sciences NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions